Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model

Cancer Immunology, Immunotherapy

Volumn 60, Issue 1, 2011, Pages 99-109

  Ishizaki, Hidenobu ^a   Manuel, Edwin R ^a   Song, Guang Yun ^a   Srivastava, Tumul ^a   Sun, Sabrina ^a   Diamond, Don J ^a   Ellenhorn, Joshua D I ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cancer vaccine; Gemcitabine; Modified vaccinia Ankara (MVA); Pancreatic cancer; Survivin

Indexed keywords

CANCER VACCINE; CD11B ANTIGEN; GAMMA INTERFERON; GEMCITABINE; MODIFIED VACCINIA ANKARA VECTOR; PEPTIDE LIBRARY; SURVIVIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; C57BL 6 MOUSE; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER SURVIVAL; CARCINOMA CELL; CD8+ T LYMPHOCYTE; CELL STRAIN; CELL STRAIN PAN02; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SPLEEN CELL; SUPPRESSOR CELL; SURVIVAL TIME;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD11B; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DEOXYCYTIDINE; GENETIC VECTORS; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MYELOID CELLS; PANCREATIC NEOPLASMS; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; RECEPTORS, CELL SURFACE; REMISSION INDUCTION; REPRESSOR PROTEINS; VACCINATION; VACCINIA VIRUS;

EID: 79953756264     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0923-0     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statics, 2009. CA Cancer J Clin 59:225-249
2. Sohn TA, Yeo CJ, Cameron JL et al (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567-579
3. Li D, Xie K, Wolff R et al (2004) Pancreatic cancer. Lancet 363:1049-1057 (Pubitemid 38410779)
4. Griffin JF, Smalley SR, Jewell W et al (1990) Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66:56-61 (Pubitemid 20197085)
5. Sperti C, Pasquali C, Piccoli A et al (1997) Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 21:195-200 (Pubitemid 27053441)
6. Burris HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
7. Louvet C, Labianca R, Hammel P et al (2005) Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516
8. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
9. Plate JM, Shott S, Harris JE (1999) Immunoregulation in pancreatic cancer patients. Cancer Immunol Immunother 48:270-279
10. Daikeler T, Maas K, Hartmann JT et al (1997) Weekly short infusions of gemcitabine are not associated with suppression of lymphatic activity in patients with solid tumors. Anticancer Drugs 8:643-644 (Pubitemid 27373446)
11. Plate JM, Plate AE, Shott S et al (2005) Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54:915-925 (Pubitemid 40991334)
12. Casneuf VF, Demetter P, Boterberg T et al (2009) Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: An experimental study with multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy. Oncol Rep 22:105-113
13. Nowak AK, Robinson BW, Lake RA (2003) Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63:4490-4496 (Pubitemid 36951021)
14. Nowak AK, Lake RA, Marzo AL et al (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4905-4913 (Pubitemid 36554719)
15. Suzuki E, Kapoor V, Jassar AS et al (2005) Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11:6713-6721 (Pubitemid 41339014)
16. Ko HJ, Kim YJ, Kim YS et al (2007) A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 67:7477-7486
17. Ito M, Shichijo S, Tsuda N et al (2001) Molecular basis of T cell-mediated recognition of pancreatic cancer cells. Cancer Res 61:2038-2046 (Pubitemid 32692025)
18. Schnurr M, Galambos P, Scholz C et al (2001) Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 61:6445-6450 (Pubitemid 32783250)
19. Schmitz-Winnenthal FH, Volk C, Z'graggen K et al (2005) High frequencies of functional tumor-reactive T cells in bonemarrow and blood of pancreatic cancer patients. Cancer Res 65:10079-10087 (Pubitemid 41541490)
20. Fukunaga A, Miyamoto M, Cho Y et al (2004) CD8+ tumorin-filtrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28:e26-e31
21. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61-70
22. Adida C, Crotty PL, McGrath J et al (1998) Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 152:43-49 (Pubitemid 28028045)
23. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921 (Pubitemid 27353455)
24. Velculescu VE, Madden SL, Zhang L et al (1999) Analysis of human transcriptomes. Nat Genet 23:387-388
25. Yamamoto H, Ngan CY, Monden M (2008) Cancer cells survive with survivin. Cancer Sci 99:1709-1714
26. Altieri DC (2006) Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 5:478-482
27. Andersen MH, Pedersen LO, Capeller B et al (2001) Spontaneous cytotoxic T-cell responses against survivin-derived MHC class Irestricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964-5968 (Pubitemid 32768582)
28. Rohayem J, Diestelkoetter P, Weigle B et al (2000) Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 60:1815-1817 (Pubitemid 30207636)
29. Xiang R, Mizutani N, Luo Y et al (2005) A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 65:553-561
30. Zeis M, Siegel S, Wagner A et al (2003) Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 170:5391-5397 (Pubitemid 36617824)
31. Sarela AI, Verbeke CS, Ramsdale J et al (2002) Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 86:886-892 (Pubitemid 34271023)
32. Kami K, Doi R, Koizumi M et al (2005) Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 138:299-305 (Pubitemid 41253814)
33. Satoh K, Kaneko K, Hirota M et al (2001) Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 92:271-278 (Pubitemid 32664432)
34. Espenschied J, Lamont J, Longmate J et al (2003) CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 170:3401-3407 (Pubitemid 36302220)
35. Daftarian P, Song GY, Ali S et al (2004) Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res 64:5407-5414 (Pubitemid 39006563)
36. Song GY, Gibson G, Haq W et al (2007) An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol Immunother 56:1193-1205 (Pubitemid 46763934)
37. Harrop R, Connolly N, Redchenko I et al (2006) Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 12:3416-3424
38. Corbett TH, Roberts BJ, Leopold WR et al (1984) Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 44:717-726 (Pubitemid 14184610)
39. Tan MC, Goedegebuure PS, Belt BA et al (2009) Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 182:1746-1755
40. Macpherson I, Stoker M (1962) Polyoma transformation of hamster cell clones - an investigation of genetic factors affecting cell competence. Virology 16:147-151
41. Dialynas DP, Wilde DB, Marrack P et al (1983) Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev 74:29-56 (Pubitemid 13050835)
42. Miconnet I, Coste I, Beermann F et al (2001) Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction. J Immunol 166:4612-4619 (Pubitemid 32233747)
43. Wang Z, La Rosa C, Mekhoubad S et al (2004) Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 104:847-856 (Pubitemid 38970584)
44. Manuel ER, Wang Z, Li Z et al (2010) Intergenic region 3 of modified vaccinia Ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses. Virology 403:155-162
45. Ishizaki H, Song GY, Srivastava T et al (2010) Heterologous prime/boost with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression. J Immunother 33:609-617
46. Gallina G, Dolcetti L, Serafini P et al (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8? T cells. J Clin Invest 116:2777-2790 (Pubitemid 44511641)
47. Rabinovich GA, Gabrilovich D, Sotomayor EM (2007) Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25:267-296 (Pubitemid 46697910)
48. Gabrilovich DI, Velders MP, Sotomayor EM et al (2001) Mechanism of immune dysfunction in cancer mediated by immature Gr-1? myeloid cells. J Immunol 166:5398-5406 (Pubitemid 32374159)
49. Serafini P, Borrello I, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16:53-65 (Pubitemid 43139709)
50. Kusmartsev S, Cheng F, Yu B et al (2003) All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63:4441-4449 (Pubitemid 36951016)
51. Serafini P, Meckel K, Kelso M et al (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203: 2691-2702 (Pubitemid 44833345)
52. Ozao-Choy J, Ma G, Kao J et al (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69:2514-2522